* Abcellera Biologics Inc ABCL.OQ reported quarterly
adjusted
earnings of 21 cents per share for the quarter ended in
December. The mean expectation of nine analysts for the quarter
was for a loss of one cent per share.
* Revenue rose 79.1% to $249.55 million from a year ago;
analysts
expected $50.80 million.
* Abcellera Biologics Inc's reported EPS for the quarter was
21
cents.
* The mean earnings estimate of analysts had risen by
about 49.7%
in the last three months.
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company.
* Abcellera Biologics Inc shares had fallen by 5.3% this
quarter.
* The company reported quarterly net income of $65 million.
* Wall Street's median 12-month price target for Abcellera
Biologics Inc is $29.50
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
This summary was machine generated from Refinitiv data February
21 at 10:49 p.m. All figures in US dollars unless otherwise
stated. QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2022 -0.01 0.21 Beat
Sep. 30 2022 0.05 0.08 Beat
Jun. 30 2022 -0.02 -0.02 Met
Mar. 31 2022 0.38 0.54 Beat